Germany – Pharmaceutical products – Conclusion of non-exclusive discount agreements in accordance with Section 130a Paragraph 8 SGB V for the active ingredients etanercept (ATC L04AB01) and epoetin alfa/zeta (ATC B03XA01)
TenderZenith matches this tender's eligibility criteria against your company profile to calculate a deterministic qualification score and identify potential disqualifiers.
A structured breakdown of scope, eligibility requirements, submission steps, and key conditions — extracted directly from the official notice.
Sign in to unlock Bid Fit & AI Opportunity Intelligence
TenderZenith calculates a personalized qualification score against your company profile and extracts structured intelligence from tender documents with your 7-Day Pro Trial (No Credit Card Required).
Description & Project Overview
Section 130a Paragraph 8 and Section 130c Paragraph 8 SGB V enables health insurance companies (KK) and pharmaceutical companies to conclude framework discount agreements for the medicines to be supplied at the expense of the statutory KK. GWQ acts as a company for efficiency and quality at KK in accordance with Section 130a Paragraph 8 Sentence 5 SGBV for its shareholders and customer funds. With regard to the relevant legal regulations for the awarding of public contracts, a regular process of active ingredient-related, formal award procedures takes place in accordance with the regulations of Part 4 of the GWB by the GWQ
Related Procurement Opportunities
Similar tenders in Pharmaceuticals